← Leaderboards
Jianren Mao
Massachusetts General Hospital
$21,748,037
Attributed
$24,408,651
Total exposure
17
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,185,831 · 18
By mechanism
R01$19,489,961 · 11
P20$5,311,628 · 3
UG3$1,365,701 · 1
R33$811,652 · 1
U24$789,389 · 1
R61$417,500 · 1
Top collaborators
- John J. A. Marota5 shared
- Lei Xu3 shared
- Hao Deng1 shared
- Alexander Nagrebetsky1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Jeevendra Martyn$10,698,401
- Xandra Owens Breakefield$30,735,276
- Anat Olga Stemmer-Rachamimov$1,001,767
- Gary Jay Brenner$3,851,453
- Lei Xu$1,353,153
Others in their field
Top investigators on “Pain”
- Emer Leahy · Psychogenics, Inc.$49,781,254
- Lynn Larson Debar · Kaiser Foundation Research Institute$37,527,482
- J Richard Landis · University Of Pennsylvania$34,799,488
- Clifford J Woolf · Boston Children'S Hospital$30,992,766
- Emeran A Mayer · University Of California Los Angeles$29,229,798
- Pamela Susan Douglas · Duke University$28,862,172
Research focus
PainChronic PainPlayBehavioralPain ManagementResponseNovel TherapeuticsResearch StudyMediatingRattusEnzyme-Linked Immunosorbent AssayImmunocytochemistryIn Situ HybridizationBehaviorNociceptionOpioidPreventOutcome StudyMorphineBrainPeripheral Nerve InjuryAnimalsHyperalgesiaAttenuated
Grant awards (62)
Deranged Gut Homeostasis and the Pathogenesis of Fibromyalgia$1,931,124
R01 · FY2025 · AR · contact PI
Continuous Monitoring of Pain using Facial Expressions in ICU Environment (COMPANION)$1,365,701
UG3 · FY2025 · NS
Establishment and Validation of a Novel Animal Model of Fibromyalgia$811,652
R33 · FY2025 · NS · contact PI
Co-Targeting IL-6 and EGFRsignaling for the Treatment of Schwannomatosis and Associated Pain$429,559
R01 · FY2025 · NS
Co-Targeting IL-6 and EGFRsignaling for the Treatment of Schwannomatosis and Associated Pain$462,970
R01 · FY2024 · NS
Establishment and Validation of a Novel Animal Model of Fibromyalgia$417,500
R61 · FY2024 · NS · contact PI
Co-Targeting IL-6 and EGFRsignaling for the Treatment of Schwannomatosis and Associated Pain$477,289
R01 · FY2023 · NS
Specialized Clinical Center at MGH for the Early Phase Pain Investigation Clinical Network$789,389
U24 · FY2019 · NS · contact PI
Combination Therapy with Opioid and Duloxetine for Chronic Pain Management$483,527
R01 · FY2019 · DA · contact PI
Combination Therapy with Opioid and Duloxetine for Chronic Pain Management$483,527
R01 · FY2018 · DA · contact PI
Alleviating Opioid-Induced Hyperalgesia with Novel Pharmacotherapy$435,000
R01 · FY2018 · DA · contact PI
Combination Therapy with Opioid and Duloxetine for Chronic Pain Management$483,527
R01 · FY2017 · DA · contact PI
Alleviating Opioid-Induced Hyperalgesia with Novel Pharmacotherapy$435,000
R01 · FY2017 · DA · contact PI
Alleviating Opioid-Induced Hyperalgesia with Novel Pharmacotherapy$430,650
R01 · FY2016 · DA · contact PI
A Model and Mechanism of the Comorbid Interaction between Pain and Anxiety$429,450
R01 · FY2016 · DE · contact PI
Alleviating Opioid-Induced Hyperalgesia with Novel Pharmacotherapy$471,814
R01 · FY2015 · DA · contact PI
A Model and Mechanism of the Comorbid Interaction between Pain and Anxiety$429,450
R01 · FY2015 · DE · contact PI
A Model and Mechanism of the Comorbid Interaction between Pain and Anxiety$429,450
R01 · FY2014 · DE · contact PI
Alleviating Opioid-Induced Hyperalgesia with Novel Pharmacotherapy$44,000
R01 · FY2014 · DA · contact PI
Alleviating Opioid-Induced Hyperalgesia with Novel Pharmacotherapy$435,000
R01 · FY2013 · DA · contact PI
A Model and Mechanism of the Comorbid Interaction between Pain and Anxiety$412,272
R01 · FY2013 · DE · contact PI
A Model and Mechanism of the Comorbid Interaction between Pain and Anxiety$429,854
R01 · FY2012 · DE · contact PI
Central Mechanisms of Orofacial Pain$346,955
R01 · FY2012 · DE · contact PI
Translational Research on Prescription Drug Abuse$928,141
P20 · FY2011 · DA · contact PI
Cellular Mechanisms of the Interaction Between Pain and Opioid Addiction$413,520
P20 · FY2011 · DA · contact PI
COMORBIDITY BETWEEN DEPRESSION AND OROFACIAL PAIN$380,958
R01 · FY2011 · DE · contact PI
Central Mechanisms of Orofacial Pain$339,946
R01 · FY2011 · DE · contact PI
Administrative Core$138,284
P20 · FY2011 · DA · contact PI
Translational Research on Prescription Drug Abuse$948,686
P20 · FY2010 · DA · contact PI
OPIOID-INDUCED PAIN SENSITIVITY: CLINICAL DIAGNOSIS AND MANAGEMENT$410,451
R01 · FY2010 · DA · contact PI
COMORBIDITY BETWEEN DEPRESSION AND OROFACIAL PAIN$392,741
R01 · FY2010 · DE · contact PI
Central Mechanisms of Orofacial Pain$350,460
R01 · FY2010 · DE · contact PI
Cellular Mechanisms of the Interaction Between Pain and Opioid Addiction$250,904
P20 · FY2010 · DA · contact PI
Administrative Core$83,915
P20 · FY2010 · DA · contact PI
Translational Research on Prescription Drug Abuse$953,831
P20 · FY2009 · DA · contact PI
OPIOID-INDUCED PAIN SENSITIVITY: CLINICAL DIAGNOSIS AND MANAGEMENT$414,597
R01 · FY2009 · DA · contact PI
COMORBIDITY BETWEEN DEPRESSION AND OROFACIAL PAIN$396,708
R01 · FY2009 · DE · contact PI
Central Mechanisms of Orofacial Pain$353,667
R01 · FY2009 · DE · contact PI
Cellular Mechanisms of the Interaction Between Pain and Opioid Addiction$245,685
P20 · FY2009 · DA · contact PI
Administrative Core$82,173
P20 · FY2009 · DA · contact PI
Translational Research on Prescription Drug Abuse$946,522
P20 · FY2008 · DA · contact PI
OPIOID-INDUCED PAIN SENSITIVITY: CLINICAL DIAGNOSIS AND MANAGEMENT$414,597
R01 · FY2008 · DA · contact PI
COMORBIDITY BETWEEN DEPRESSION AND OROFACIAL PAIN$396,708
R01 · FY2008 · DE · contact PI
Central Mechanisms of Orofacial Pain$351,667
R01 · FY2008 · DE · contact PI
Cellular Mechanisms of the Interaction Between Pain and Opioid Addiction$240,563
P20 · FY2008 · DA · contact PI
Administrative Core$79,404
P20 · FY2008 · DA · contact PI
OPIOID-INDUCED PAIN SENSITIVITY: CLINICAL DIAGNOSIS AND MANAGEMENT$423,058
R01 · FY2007 · DA · contact PI
COMORBIDITY BETWEEN DEPRESSION AND OROFACIAL PAIN$401,120
R01 · FY2007 · DE · contact PI
Glutamate Uptake & the Pathogenesis of Neuropathic Pain$344,627
R01 · FY2007 · NS · contact PI
OPIOID-INDUCED PAIN SENSITIVITY: CLINICAL DIAGNOSIS AND MANAGEMENT$435,693
R01 · FY2006 · DA · contact PI
Glutamate Uptake & the Pathogenesis of Neuropathic Pain$354,941
R01 · FY2006 · NS · contact PI
Neuropathic Pain Modulation by Cannabinoids$318,944
R01 · FY2006 · NS · contact PI
Glutamate Uptake &the Pathogenesis of Neuropathic Pain$363,504
R01 · FY2005 · NS
Cellular Mechanisms of Hyperalgesia and Opioid Tolerance$346,000
R01 · FY2005 · DA
Neuropathic Pain Modulation by Cannabinoids$326,620
R01 · FY2005 · NS
Glutamate Uptake &the Pathogenesis of Neuropathic Pain$382,796
R01 · FY2004 · NS
Cellular Mechanisms of Hyperalgesia and Opioid Tolerance$346,000
R01 · FY2004 · DA
Neuropathic Pain Modulation by Cannabinoids$326,620
R01 · FY2004 · NS
Neuropathic Pain Modulation by Cannabinoids$374,120
R01 · FY2003 · NS
Cellular Mechanisms of Hyperalgesia and Opioid Tolerance$346,000
R01 · FY2003 · DA
Cellular Mechanisms of Hyperalgesia and Opioid Tolerance$346,000
R01 · FY2002 · DA
Cellular Mechanisms of Hyperalgesia and Opioid Tolerance$371,000
R01 · FY2001 · DA